casemark/informed-consent-form

Informed Consent Form

Drafts a defensible informed consent form satisfying disclosure obligations and documenting voluntary, knowing authorization.

Quick Start

Gather before drafting:

1. Jurisdiction — which consent standard applies (professional, reasonable person, or subjective)
2. Regulatory framework — HIPAA, FDA, IRB/Common Rule, ICH-GCP, state rules
3. Procedure details — protocol, personnel, timeline, devices, medications
4. Participant population — capacity issues, language needs, literacy level
5. Institutional requirements — templates, mandatory language, formatting

Core Sections

1. Procedure Description

| Element | Include | |---|---| | Process overview | Prep, intervention, follow-up in plain language; define terms parenthetically | | Timeline | Frequency, duration, total commitment | | Personnel | Qualifications of those performing/supervising | | Materials | Equipment, medications, devices with lay explanations | | Participant burden | Physical demands, time, lifestyle changes, emotional impact |

2. Risk Disclosure and Benefits

Risk frequency tiers — use consistently:

| Tier | Frequency | Label | |---|---|---| | Common | >10% | "commonly" / "frequently" | | Occasional | 1–10% | "occasionally" / "sometimes" | | Rare | <1% | "rarely" | | Isolated | Case reports only | "in isolated cases" |

For each material risk: nature of harm, severity, temporary vs. permanent, mitigation.

Benefits: realistic expectations only, no guarantees. State if experimental. Include statistical context when available.

3. Alternatives and Right to Refuse

• [ ] Each viable alternative with comparative risk/benefit/cost analysis
• [ ] Less invasive options and conservative management
• [ ] Option to decline — natural course explained factually
• [ ] No-coercion language: refusal won't cause abandonment or care loss
• [ ] If no alternatives exist, state clinical basis

4. Privacy and Information Governance

• [ ] Data collected, purpose, retention, access (care team, researchers, regulators)
• [ ] Applicable privacy framework (HIPAA, FERPA, state statutes)
• [ ] Confidentiality limits: mandatory reporting, court orders, safety exceptions
• [ ] Secondary uses require separate consent (QI, teaching, research, publication)
• [ ] Safeguards described; participant rights to access/correct data
• [ ] Certificate of Confidentiality status (research)

5. Participant Rights and Withdrawal

• [ ] Unconditional right to withdraw without penalty
• [ ] Withdrawal process: contact, written notice, data/specimen disposition
• [ ] Honest disclosure of practical limitations (irreversible steps, published aggregates)
• [ ] Right to ask questions at any point
• [ ] Contact info for questions, adverse events, complaints
• [ ] Financial transparency: covered costs, out-of-pocket, compensation

6. Signature and Execution Block

Include all that apply:

Primary participant — attestations: read/understood, opportunity to ask questions, voluntary consent. Signature, printed name, date.

Authorized representative (if participant lacks capacity) — signature, printed name, date, relationship, legal basis for authority.

Person obtaining consent — attestation that procedure was explained and participant demonstrated understanding. Signature, printed name/title, date.

Witness (when required by regulation/policy) — attestation of observing consent process. Signature, printed name, date.

Separate opt-in/opt-out blocks for each ancillary authorization:

• Photography/video
• Specimen use for future research
• Contact for additional studies
• Third-party information release

Document control footer: version number, effective date, supersedes date, page X of Y.

Include statement: participant receives a complete signed copy.

Drafting Rules

1. Jurisdiction-first — confirm applicable consent standard before drafting; requirements vary by state
2. Plain language — active voice, short sentences, common words; define technical terms parenthetically; 12pt minimum font
3. Material risk standard — disclose any risk a reasonable person would consider significant; err toward over-disclosure
4. No guarantees — use "may," "expected," "typical"; never promise outcomes
5. Selective consent — participants must decline ancillary authorizations without affecting primary consent
6. Capacity accommodations — address literacy, language, cognitive limitations in the attestation

Pitfalls

• Skipping jurisdictional analysis — consent standards differ significantly by state; a form valid in one may be inadequate in another
• Burying risks — material risks must be prominent, not hidden in dense paragraphs
• Coercive framing — refusal language must be neutral; never imply negative consequences for declining
• Missing withdrawal limits — state honestly which steps are irreversible; omission undermines defensibility

Final Check

• [ ] Applicable regulatory frameworks identified and addressed
• [ ] All material risks disclosed with frequency tier labels
• [ ] Alternatives section includes option to decline
• [ ] Privacy section covers confidentiality limitations
• [ ] Signature blocks match participant population (capacity, witnesses)
• [ ] Ancillary authorizations are separate opt-in/opt-out
• [ ] Document control footer with version, date, pagination
• [ ] Flag for review by legal counsel, compliance, and IRB/ethics committee (if research)